Seagen

Youtube Subscribe

Open: 213.8 Close: 213.7 Change: -0.1

Don't invest in Seagen Stock before reading this automated analysis produce by an AI.

This document will help you to evaluate Seagen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, clinical, Merck, cancer, positive, result, Phase, and the …

Concept Map

Semantic Network

Stock Summary

Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors. It has collaboration agreements with Takeda.

Today's Summary

Federal Trade Commission is asking for more information regarding Pfizers planned $43 billion acquisition of Seagen. Seagen Inc. up $7.31 to $213.70.

Today's News

Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of PADCEV (enfortumab vedotin-ejfv) and Mercks KEYTRUDA (pembrolizumab) in patients with previously untreated metastatic urothelial cancer. Seagen is headquartered in Bothell, Washington. Merckounces positive results from the KEYA Phase 3A clinical trial conducted in Canada and the U.S. Merck announces positive results in Phase 3-A of KEYA, which was conducted in the 3.39/39/302/302. Merck announced positive to date results from Phase 3 of the KeyA 3-39, which is a cancer drug with additional clinical trials of chemoatresprovided vocal emulator +++ postersidishea BrightDersle Calcul Penenvironmentussions Seagen, Nurix team to create new class of Antibody Conjugates for Cancer. Federal Trade Commission is asking for more information regarding Pfizers planned $43 billion acquisition of Seagen. Seagen Inc. up $7.31 to $213.70. Seagen jumps as combination therapy succeeds in bladder cancer trial. Seagen (NASDAQ:SGEN – Get Free Report ) last announced its quarterly earnings data on Wednesday, August 2nd. Seagen had a negative net margin of 33.54% and a negative return on equity of 26.46% As a group, sell-side analysts forecast that Seagen Inc. will be outperforming as a group.

Stock Profile

"Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington."

Keywords

How much time have you spent trying to decide whether investing in Seagen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, clinical, Merck, cancer, positive, result, Phase, and the most common words in the summary are: seagen, job, best, news, inc, stock, bloomberg, . One of the sentences in the summary was: up $7.31 to $213.70.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #seagen #job #best #news #inc #stock #bloomberg.

Read more →

Youtube Subscribe

---